Clinical Trial

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Name: 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer — clinical trial record (NCT06592326)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a randomized, controlled, open-label, multicenter phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of 9MW2821 combined with Toripalimab versus standard chemotherapy in first-line locally advanced or metastatic urothelial cancer.

Trial Details

NCT Number	NCT06592326
Lead Sponsor	Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions	Urothelial Carcinoma
Enrollment	460 participants
Start Date	2024-08-22
Primary Completion	2027-09 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2024-09-19